Peter Clark to Combined Modality Therapy
This is a "connection" page, showing publications Peter Clark has written about Combined Modality Therapy.
Connection Strength
0.332
-
Morgan TM, Clark PE. Bladder cancer. Curr Opin Oncol. 2010 May; 22(3):242-9.
Score: 0.083
-
Clark PE. Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer. Expert Rev Anticancer Ther. 2009 Jun; 9(6):821-30.
Score: 0.078
-
Gwynn ES, Clark PE. Bladder cancer. Curr Opin Oncol. 2006 May; 18(3):277-83.
Score: 0.063
-
Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 10; 15(10):1240-1267.
Score: 0.035
-
Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, Pruthi R, Quale DZ, Ritch CR, Seigne JD, Skinner EC, Smith ND, McKiernan JM. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. J Urol. 2016 Oct; 196(4):1021-9.
Score: 0.032
-
Azawi NH, Joergensen SM, Jensen NV, Clark PE, Lund L. Trends in kidney cancer among the elderly in Denmark, 1980-2012. Acta Oncol. 2016; 55 Suppl 1:79-84.
Score: 0.031
-
Borden LS, Clark PE, Hall MC. Bladder cancer. Curr Opin Oncol. 2003 May; 15(3):227-33.
Score: 0.013